Invivyd, Inc. - Common Stock IVVD 深 滬
已收盤 12-12 16:00:00 美东时间
2.32
-0.060
-2.52%
華盛通- 最 高2.435
- 今 開2.36
- 成交量 276.99万股
- 最 低 2.305
- 昨 收 2.38
- 總市值 6.43亿
- 52周最高 3.0699
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 0.3546
- 委 比 72.84%
- 總股本 2.77亿
- 歷史最高 78.82
- 量 比 0.68
- 振 幅 5.46%
- 歷史最低 0.3546
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多D. Boral Capital Downgrades Invivyd to Hold
D. Boral Capital analyst Jason Kolbert downgrades Invivyd (NASDAQ:IVVD) from Buy to Hold.
11-25 21:03
Invivyd shares are trading lower after the company announced a proposed public offering.
Invivyd shares are trading lower after the company announced a proposed public ...
11-18 05:07
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling more than 500 points o...
11-14 22:54
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of RLX Technology Inc – ADR (NYSE:RLX) rose sharply in pre-market tradin...
11-14 18:52
Invivyd shares are trading higher after the company reported better-than-expected Q3 financial results.
Invivyd shares are trading higher after the company reported better-than-expect...
11-06 22:28
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Examining the Future: Invivyd's Earnings Outlook
Invivyd (NASDAQ:IVVD) is set to give its latest quarterly earnings report on Th...
11-06 03:02
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd, Inc. will host a live webcast on October 30, 2025, at 8:30 a.m. ET to discuss its REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention. Key executives, including Marc Elia, Tim Lee, Robert Allen, PhD, and Mark Wingertzahn, PhD, will participate. VYD2311 is designed to address the need for new prophylactic options and may offer patient-friendly administration. The webcast will provide details on...
10-28 11:01
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
